CN109796418A - Phenylalanine derivative and the preparation method and application thereof containing 4- phenyl -1,2,3- triazole - Google Patents
Phenylalanine derivative and the preparation method and application thereof containing 4- phenyl -1,2,3- triazole Download PDFInfo
- Publication number
- CN109796418A CN109796418A CN201910141019.0A CN201910141019A CN109796418A CN 109796418 A CN109796418 A CN 109796418A CN 201910141019 A CN201910141019 A CN 201910141019A CN 109796418 A CN109796418 A CN 109796418A
- Authority
- CN
- China
- Prior art keywords
- chloride
- dichloromethane
- methyl
- phenyl
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002993 phenylalanine derivatives Chemical class 0.000 title claims abstract description 30
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical compound C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 111
- 150000001875 compounds Chemical class 0.000 claims description 50
- -1 4-methylbenzoyl Chemical group 0.000 claims description 44
- 239000012074 organic phase Substances 0.000 claims description 31
- 230000002829 reductive effect Effects 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 14
- 238000001704 evaporation Methods 0.000 claims description 14
- 238000010898 silica gel chromatography Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- GTCLFEMMPGBNOI-UHFFFAOYSA-N 2-phenylethynamine Chemical group NC#CC1=CC=CC=C1 GTCLFEMMPGBNOI-UHFFFAOYSA-N 0.000 claims description 12
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- PPXUUPXQWDQNGO-UHFFFAOYSA-N 2-azidoacetic acid Chemical compound OC(=O)CN=[N+]=[N-] PPXUUPXQWDQNGO-UHFFFAOYSA-N 0.000 claims description 7
- JFXDIXYFXDOZIT-UHFFFAOYSA-N 4-methoxy-n-methylaniline Chemical compound CNC1=CC=C(OC)C=C1 JFXDIXYFXDOZIT-UHFFFAOYSA-N 0.000 claims description 7
- 150000001263 acyl chlorides Chemical class 0.000 claims description 7
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 7
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 7
- 229960005055 sodium ascorbate Drugs 0.000 claims description 7
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 claims description 5
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 claims description 5
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 claims description 5
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 claims description 5
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 claims description 5
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 claims description 5
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 claims description 5
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012346 acetyl chloride Substances 0.000 claims description 5
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 238000006482 condensation reaction Methods 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- ALQPJHSFIXARGX-UHFFFAOYSA-N 2-ethynylaniline Chemical group NC1=CC=CC=C1C#C ALQPJHSFIXARGX-UHFFFAOYSA-N 0.000 claims description 3
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical group NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 claims description 3
- JXYITCJMBRETQX-UHFFFAOYSA-N 4-ethynylaniline Chemical group NC1=CC=C(C#C)C=C1 JXYITCJMBRETQX-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 230000036436 anti-hiv Effects 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 238000006352 cycloaddition reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 229940124321 AIDS medicine Drugs 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 337
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 164
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 52
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 42
- 230000003595 spectral effect Effects 0.000 description 42
- 238000002844 melting Methods 0.000 description 39
- 230000008018 melting Effects 0.000 description 39
- 239000007787 solid Substances 0.000 description 39
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 38
- 239000000543 intermediate Substances 0.000 description 23
- 208000031886 HIV Infections Diseases 0.000 description 22
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 21
- PDLKWXOMAIFECT-DEOSSOPVSA-N (2S)-2-[[2-[4-(4-aminophenyl)triazol-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound NC1=CC=C(C=C1)C=1N=NN(C=1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 PDLKWXOMAIFECT-DEOSSOPVSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- WYUZPGNUASMCFI-DEOSSOPVSA-N (2S)-2-[[2-[4-(3-aminophenyl)triazol-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound NC=1C=C(C=CC=1)C=1N=NN(C=1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 WYUZPGNUASMCFI-DEOSSOPVSA-N 0.000 description 17
- HFUSWJKRRCIEJM-DEOSSOPVSA-N (2S)-2-[[2-[4-(2-aminophenyl)triazol-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound NC1=C(C=CC=C1)C=1N=NN(C=1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 HFUSWJKRRCIEJM-DEOSSOPVSA-N 0.000 description 16
- 108090000565 Capsid Proteins Proteins 0.000 description 11
- 102100023321 Ceruloplasmin Human genes 0.000 description 11
- OYKDVLVJUHEVGV-KRWDZBQOSA-N (2S)-2-[(2-azidoacetyl)amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound N(=[N+]=[N-])CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 OYKDVLVJUHEVGV-KRWDZBQOSA-N 0.000 description 6
- RHZIAXWOSSTBDM-INIZCTEOSA-N (2s)-2-amino-n-(4-methoxyphenyl)-n-methyl-3-phenylpropanamide Chemical compound C1=CC(OC)=CC=C1N(C)C(=O)[C@@H](N)CC1=CC=CC=C1 RHZIAXWOSSTBDM-INIZCTEOSA-N 0.000 description 5
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000012268 protein inhibitor Substances 0.000 description 5
- 229940121649 protein inhibitor Drugs 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- LVYNHGFRRWJHTL-SANMLTNESA-N (2S)-2-[[2-[4-(2-acetamidophenyl)triazol-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound C(C)(=O)NC1=C(C=CC=C1)C=1N=NN(C=1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 LVYNHGFRRWJHTL-SANMLTNESA-N 0.000 description 1
- IADHMVZLXNSYBG-SANMLTNESA-N (2S)-2-[[2-[4-(3-acetamidophenyl)triazol-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound C(C)(=O)NC=1C=C(C=CC=1)C=1N=NN(C=1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 IADHMVZLXNSYBG-SANMLTNESA-N 0.000 description 1
- ZCBNBVPQIFOETJ-SANMLTNESA-N (2S)-2-[[2-[4-(4-acetamidophenyl)triazol-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound C(C)(=O)NC1=CC=C(C=C1)C=1N=NN(C=1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1 ZCBNBVPQIFOETJ-SANMLTNESA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 101710164563 Beta-catenin-like protein 1 Proteins 0.000 description 1
- 102100031109 Beta-catenin-like protein 1 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JITKTORUUMSCJD-HKBQPEDESA-N N-[2-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]-4-methylbenzamide Chemical compound CC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2C3=CN(N=N3)CC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N(C)C5=CC=C(C=C5)OC JITKTORUUMSCJD-HKBQPEDESA-N 0.000 description 1
- YQBQOIHNGFHGHM-BHVANESWSA-N N-[2-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]-4-phenylbenzamide Chemical compound CN(C1=CC=C(C=C1)OC)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN3C=C(N=N3)C4=CC=CC=C4NC(=O)C5=CC=C(C=C5)C6=CC=CC=C6 YQBQOIHNGFHGHM-BHVANESWSA-N 0.000 description 1
- FNRUOEXNWSZVFC-PMERELPUSA-N N-[2-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]benzamide Chemical compound CN(C1=CC=C(C=C1)OC)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN3C=C(N=N3)C4=CC=CC=C4NC(=O)C5=CC=CC=C5 FNRUOEXNWSZVFC-PMERELPUSA-N 0.000 description 1
- XZLINYRBJCOWAX-HKBQPEDESA-N N-[3-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]-4-methylbenzamide Chemical compound CC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)C3=CN(N=N3)CC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N(C)C5=CC=C(C=C5)OC XZLINYRBJCOWAX-HKBQPEDESA-N 0.000 description 1
- FZQRLWCHRDZBIB-BHVANESWSA-N N-[3-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]-4-phenylbenzamide Chemical compound CN(C1=CC=C(C=C1)OC)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN3C=C(N=N3)C4=CC(=CC=C4)NC(=O)C5=CC=C(C=C5)C6=CC=CC=C6 FZQRLWCHRDZBIB-BHVANESWSA-N 0.000 description 1
- QOWOEMBXKGMSOL-PMERELPUSA-N N-[3-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]benzamide Chemical compound CN(C1=CC=C(C=C1)OC)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN3C=C(N=N3)C4=CC(=CC=C4)NC(=O)C5=CC=CC=C5 QOWOEMBXKGMSOL-PMERELPUSA-N 0.000 description 1
- DOOUIZORRQRMBJ-HKBQPEDESA-N N-[4-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]-4-methylbenzamide Chemical compound CC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(N=N3)CC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N(C)C5=CC=C(C=C5)OC DOOUIZORRQRMBJ-HKBQPEDESA-N 0.000 description 1
- DXVHOPMYNLYQHM-PMERELPUSA-N N-[4-[1-[2-[[(2S)-1-(4-methoxy-N-methylanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]triazol-4-yl]phenyl]benzamide Chemical compound CN(C1=CC=C(C=C1)OC)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN3C=C(N=N3)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5 DXVHOPMYNLYQHM-PMERELPUSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229940124765 capsid inhibitor Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of phenylalanine derivatives and its preparation method and application containing 4- phenyl -1,2,3- triazole.The derivative has structure shown in following general formula I.The application in anti-AIDS drug is being prepared the invention further relates to the preparation method of the analog derivative and its as hiv inhibitor.
Description
Technical Field
The invention belongs to the technical field of organic compound synthesis and medical application, and particularly relates to a phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole as well as a preparation method and application thereof.
Background
Acquired Immune Deficiency Syndrome (AIDS) is a serious infectious disease that endangers Human life and health, mainly caused by Human Immunodeficiency Virus Type I (HIV-1). Currently, clinically applied drugs for treating aids mainly include: reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and fusion inhibitors. The high-efficiency Antiretroviral Therapy (HAART) prolongs the survival time of patients to a great extent and improves the life quality of the patients, but the drug resistance problem, the drug toxic and side effects, the latent infection, the high cost of taking the drug for a long time and the like greatly reduce the efficacy of the Therapy, limit the application of the Therapy and further force researchers to develop anti-AIDS drugs with new targets, new mechanisms and new structures.
The HIV-1 capsid is assembled from a portion of the Gag precursor protein that is cleaved to yield capsid protein units. During the conversion of immature virions to mature virions, capsid proteins assemble into capsids, encapsulating viral RNA and nuclear-associated proteins (reverse transcriptase, protease, integrase, etc.) to form mature HIV-1 virions. The mature virion is infectious and can undergo the next round of replication of the virus. In recent years, with the researchers' deep knowledge of capsid protein structure, the related information of crystal structure is reported in succession. Thus, the capsid protein of HIV-1 can be used as a new anti-HIV-1 action target.
The Pfizer company obtains a compound PF-74 capable of obviously inhibiting HIV-1 replication through high-throughput screening of a compound library, and the structure-activity relationship and mechanism research of the compound shows that the compound interferes with the uncoating process of viruses and the process of forming infectious particles by combining HIV-1 capsid protein. Although PF-74 has novel structure, unique mechanism and definite target, PF-74 has lower curative effect, poorer drug-like property and is easy to induce drug resistance compared with the anti-HIV-1 drug on the market at present. Therefore, the development of capsid protein inhibitors with higher efficacy and good drug-like and drug-resistance has become an attractive direction in the development field of anti-aids drugs in recent years.
According to the crystal structure characteristics of the binding site of the PF-74 and HIV-1 capsid protein, the phenylalanine HIV-1 capsid protein inhibitor of benzene sulfonamide of 4-phenyl-1, 2, 3-triazole with a brand-new structure is discovered through reasonable drug design, chemical synthesis and biological activity evaluation, and the problems of poor drug property and drug resistance of the existing HIV-1 capsid protein inhibitor are hopefully relieved.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and a preparation method thereof, and also provides an activity screening result of the compound as an HIV-1 capsid protein inhibitor and application thereof.
The technical scheme of the invention is as follows:
1. phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole
The phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole, or pharmaceutically acceptable salt, ester or prodrug thereof has a structure shown in a general formula I:
wherein,
the amido is ortho-substituted, meta-substituted or para-substituted of benzene ring; r is: H. acetyl, benzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methoxybenzoyl, 3-methoxybenzoyl, 4-methyl formate benzoyl, 3-methyl formate benzoyl, 2-methyl formate benzoyl, 4-cyanobenzoyl, 3-cyanobenzoyl, 2-fluorobenzoyl, 3-fluorobenzoyl, 4-phenylbenzoyl, 3-phenylbenzoyl, 2-phenylbenzoyl.
According to the invention, the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole is one of the following compounds:
as used herein, "pharmaceutically acceptable salts" means salts of the compounds which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and lower animals without undue toxicity, irritation, and allergic response and the like, are commensurate with a reasonable benefit-to-risk ratio, are generally water or oil soluble or dispersible, and are effective for their intended use. Including pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts, which are contemplated herein and are compatible with the chemical nature of the compounds of formula I. A list of suitable salts is found on pages 1-19 of s.m. berge et al, j.pharm.sci.,1977, 66.
The term "prodrug" as used herein refers to pharmaceutically acceptable derivatives such that the resulting biotransformation product of these derivatives is the active drug as defined for the compound of formula I.
2. Preparation method of phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole
The preparation method of the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole comprises the following steps: generating an intermediate 2 with Boc-L-phenylalanine (1) as an initial raw material and dichloromethane as a reaction solvent through an amide condensation reaction and N-methyl-4-aminoanisole; then the intermediate 2 is dissolved in a proper amount of dichloromethane, and Boc groups are removed under the action of trifluoroacetic acid to obtain an intermediate 3; then, carrying out amide condensation reaction on the intermediate 3 and azido acetic acid to obtain an intermediate 4 with azido groups; the intermediate 4 and corresponding substituted aminophenylacetylene generate compounds 5a-5c through azide-alkyne Husigen-Click cycloaddition reaction catalyzed by Cu (I) under the condition of sodium ascorbate and copper sulfate pentahydrate; finally, the compounds 5a-5c and corresponding acyl chloride are subjected to acylation reaction to obtain the target compounds 6a- (1-12), 6b- (1-12) and 6c- (1-12).
The synthetic route is as follows:
reagents and conditions: (i) n-methyl-4-aminoanisole, 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate, N, N-diisopropylethylamine and dichloromethane are added, and the temperature is changed to room temperature at 0 ℃; (ii) trifluoroacetic acid, dichloromethane, room temperature; (iii) azidoacetic acid, O- (7-azabenzotriazole-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, N, N-diisopropylethylamine and acetonitrile, and the temperature is changed to room temperature at 0 ℃; (iv) corresponding substituted aminophenylacetylene, sodium ascorbate, copper sulfate pentahydrate, water/tetrahydrofuran, room temperature; (v) the corresponding acid chloride, triethylamine and dichloromethane are cooled to room temperature at 0 ℃.
Wherein R is as described in formula I above.
The substituted aminophenylacetylene is 2-aminophenylacetylene, 3-aminophenylacetylene or 4-aminophenylacetylene.
The acyl chloride is acetyl chloride, benzoyl chloride, 4-methylbenzoyl chloride, 2-methoxybenzoyl chloride, 3-methoxybenzoyl chloride, 4-methyl formate benzoyl chloride, 4-cyanobenzoyl chloride, 2-fluorobenzoyl chloride, 3-fluorobenzoyl chloride, 4-fluorobenzoyl chloride or 4-phenylbenzoyl chloride.
The room temperature of the invention is 20-30 ℃.
According to the preferable preparation method of the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole, the preparation method comprises the following specific steps:
(1) adding Boc-L-phenylalanine (1) and 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate into dichloromethane, and stirring for 30min under an ice bath condition; adding N, N-diisopropylethylamine and N-methyl-4-aminoanisole into the reaction solution, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium bicarbonate solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, adding a 1N HCl solution for washing, separating the organic phase, adding a saturated sodium chloride solution for washing, drying the organic phase with anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and separating and purifying the obtained crude product by silica gel column chromatography to obtain an intermediate 2;
(2) adding the intermediate 2 obtained in the previous step into dichloromethane, then slowly dropwise adding excessive trifluoroacetic acid into the solution, and stirring for 1h at room temperature; then adding saturated sodium bicarbonate solution to adjust the pH value of the reaction solution to 7, and then adding dichloromethane solution for extraction; separating and taking an organic phase, washing the organic phase for 3 times by using a saturated sodium chloride solution, drying the organic phase by using anhydrous sodium sulfate, filtering, evaporating the solvent by reduced pressure, and separating by using silica gel column chromatography to obtain an intermediate 3;
(3) adding azidoacetic acid and O- (7-azabenzotriazole-1-yl) -N, N, N ', N' -tetramethylurea hexafluorophosphate into acetonitrile, and stirring for 1h under an ice bath condition; then adding the intermediate 3 and N, N-diisopropylethylamine into the solution, removing the ice bath, and stirring at room temperature for 12 h; after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium bicarbonate solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, adding a 1N HCl solution for washing, separating the organic phase, adding a saturated sodium chloride solution for washing, drying the organic phase with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, and separating by silica gel column chromatography to obtain an intermediate 4;
(4) adding the intermediate 4, substituted aminophenylacetylene, sodium ascorbate and copper sulfate pentahydrate into a mixed solvent of tetrahydrofuran and water in a volume ratio of 1:1, and stirring at room temperature for 12 h; after the reaction is finished, adding a proper amount of saturated sodium chloride solution into the reaction solution, extracting with dichloromethane, separating and taking an organic phase, drying with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, and separating by silica gel column chromatography; recrystallizing ethyl acetate/petroleum ether to obtain compounds 5a-5 c;
(5) adding the compounds 5a-5c and triethylamine into dichloromethane, slowly adding corresponding acyl chloride into the dichloromethane under the condition of ice bath and stirring, removing the ice bath, transferring to room temperature, and monitoring by TLC; and after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium chloride solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, drying with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, separating by silica gel column chromatography to obtain a crude product of the target compound, and purifying by using a silica gel preparation plate to obtain pure products 6a- (1-12), 6b- (1-12) and 6c- (1-12) of the target compound.
3. Application of phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole
The invention discloses a screening result of anti-HIV-1 activity of a phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and application of the phenylalanine derivative as an HIV-1 inhibitor for the first time. Experiments prove that the phenylalanine derivative containing the 4-phenyl-1, 2, 3-triazole can be used as an HIV-1 inhibitor for preparing anti-AIDS medicaments. The invention also provides application of the compound in anti-HIV drugs.
anti-HIV-1 Activity and toxicity test of the target Compound
A class of phenylalanine derivatives containing 4-phenyl-1, 2, 3-triazole synthesized according to the method is subjected to anti-HIV-1 activity and toxicity tests at a cellular level, the anti-HIV-1 activity and toxicity data of the phenylalanine derivatives are listed in Table 1, and a capsid protein inhibitor PF-74 reported in the literature is taken as a positive control.
The newly synthesized phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole has obvious anti-HIV-1 activity. Example (b)For example, compounds 5a, 6a-1, 6a-2, 6a-9, 6a-10, 6a-11, 5b have anti-HIV-1 activity in the range of 3.13-3.99. mu.M, with compounds 6a-9 having anti-HIV-1 activity (EC)50=3.13±0.91μM,CC50>16.48,SI>5.27) is particularly outstanding and has value for further research.
The phenylalanine derivatives containing 4-phenyl-1, 2, 3-triazole can be used as HIV-1 inhibitors. In particular to the application of the compound as an HIV-1 inhibitor in preparing anti-AIDS drugs.
An anti-HIV-1 pharmaceutical composition comprises a phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and one or more pharmaceutically acceptable carriers or excipients.
The invention provides a phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and a preparation method thereof, and also provides a screening result of anti-HIV-1 activity of partial compounds and the first application thereof in the field of antivirus. Tests prove that the phenylalanine derivatives containing 4-phenyl-1, 2, 3-triazole can be used as HIV-1 inhibitors and have high application value. In particular to the application of the compound as an HIV-1 inhibitor in preparing anti-AIDS drugs.
Detailed Description
The invention will be understood by the following examples, which are given by way of illustration and are not intended to limit the scope of the invention.
Example 1: preparation of tert-butyl (S) - (1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) carbamate (2)
The starting material Boc-L-phenylalanine (1) (2.90g,10.93mmol,1.5eq.) and 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate (5.69g,10.93mmol,1.5eq.) were added to 20mL of dichloromethane and stirred under ice bath conditions for 30 min; then N, N-diisopropylethylamine (3.61mL,21.87mmol,3eq.) and N-methyl-4-aminoanisole (1.0g7.29mmol,1eq.) were added, the ice bath was removed and the mixture was stirred at room temperature, monitored by TLC; after 6h, the reaction was completed, the solvent was evaporated under reduced pressure, then 40mL of saturated sodium bicarbonate solution and 40mL of dichloromethane were added to the residue in the flask for extraction, the organic phase was separated and washed with 40mL of 1N HCl solution, the organic phase was separated and washed with 40mL of saturated sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude product of tert-butyl (S) - (1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) carbamate (2), which was an intermediate, 2.48g and was a yellow oily substance, with a yield of 88% by silica gel column chromatography (eluent EA: PE ═ 1:8 v/v).
Spectral data:1H NMR(400MHz,DMSO-d6)δ7.22(d,J=8.3Hz,2H,Ph-H),7.20–7.11(m,3H,Ph-H),7.09(d,J=8.2Hz,1H,NH),7.03(d,J=8.6Hz,2H,Ph-H),6.79(d,J=7.3Hz,2H,Ph-H),4.27–4.06(m,1H,CH),3.81(s,3H,OCH3),3.13(s,3H,NCH3),2.75(dd,J=13.4,3.8Hz,1H,PhCH),2.61(dd,J=13.3,10.3Hz,1H,PhCH),1.30(s,9H,C(CH3)3).13C NMR(100MHz,DMSO-d6)δ172.22(C=O),158.98,155.75(C=O),138.53(2×C),136.12(2×C),129.28(2×C),128.47(2×C),126.70,115.21(2×C),78.33,55.94,53.55,37.86,37.07,28.65(3×C).ESI-MS:m/z 385.4(M+1),407.5(M+23).C22H28N2O4[384.5].
example 2: preparation of (S) -2-amino-N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (3)
Intermediate 2(4.0g,10.40mmol,1.0eq.) was added to 30mL of dichloromethane, and trifluoroacetic acid (3.86mL,52.02mmol,5.0eq.) was then added slowly to this solution, stirred at room temperature, monitored by TLC; after 1h, the reaction was completed, and then the reaction solution was adjusted to pH 7 with saturated sodium bicarbonate solution, extracted with 40mL of dichloromethane, the organic phase was separated, washed with saturated sodium chloride solution (20 mL. times.3 times), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2.36g of a crude product of intermediate (S) -2-amino-N- (4-methoxyphenyl) -N-methyl-3-phenylacrylamide (3), as a yellow oil, in 80% yield.
Spectral data:1H NMR(400MHz,DMSO-d6)δ7.29–7.13(m,3H,Ph-H),7.03–6.75(m,6H,Ph-H),3.77(s,3H,OCH3),3.44–3.35(m,1H,CH),3.06(s,3H,NCH3),2.75(dd,J=12.8,6.7Hz,1H,PhCH),2.45(dd,J=12.9,7.1Hz,1H,PhCH),1.87(s,2H,NH2).13C NMR(100MHz,DMSO-d6)δ174.89(C=O),158.75,139.00,136.35,129.51(2×C),128.93(2×C),128.47(2×C),126.55,115.04(2×C),55.85,53.35,42.19,37.45.ESI-MS:m/z 285.05(M+1).C17H20N2O2[284.36].
example 3: preparation of intermediate (S) -2- (2-azidoacetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (4)
Azidoacetic acid (40mg,0.40mmol,1.2eq.) and O- (7-azabenzotriazol-1-yl) -N, N' -tetramethyluronium hexafluorophosphate (188mg,0.50mmol,1.5eq.) were added to 15mL acetonitrile and stirred under ice-bath conditions for 1 h; intermediate 3(94mg,0.33mmol,1eq.) and N, N-diisopropylethylamine (109 μ L,0.66mmol,2eq.) were then added to this solution, and after removal of the ice bath, stirred at room temperature and monitored by TLC; after 12 hours, the reaction was completed, the solvent was distilled off under reduced pressure, then 20mL of a saturated sodium bicarbonate solution and 20mL of dichloromethane were added to the residue in the flask for extraction, the organic phase was separated, 10mL of a 1N HCl solution was added for washing, the organic phase was separated and washed with a saturated sodium chloride solution (10mL × 3 times), the organic phase was dried over anhydrous sodium sulfate, filtered, the solvent was evaporated under reduced pressure, and silica gel column chromatography was performed (eluent EA: PE ═ 1:4) to obtain 47mg of an intermediate (S) -2- (2-azidoacetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (4) as a yellow oily substance in 39% yield.
Spectral data:1H NMR(400MHz,Methanol-d4)δ7.27–7.13(m,3H,Ph-H),7.11–6.59(m,6H,Ph-H),4.67(t,J=7.4Hz,1H,NH),3.82(s,3H,OCH3),3.81–3.74(m,1H,CH),3.31(dt,J=3.1,1.6Hz,2H,N3CH2),3.16(s,3H,NCH3),2.97(dd,J=13.3,7.0Hz,1H,PhCH),2.73(dd,J=13.3,7.9Hz,1H,PhCH).13C NMR(100MHz,Methanol-d4)δ171.05(C=O),167.29(C=O),158.67,135.77,134.23,128.05(2×C),127.49,127.30(2×C),125.75(2×C),113.66(2×C),53.79,51.03,50.30,36.99,36.05.ESI-MS:m/z 368.3(M+1),390.3(M+23),406.5(M+39).C19H21N5O3[367.4].
example 4: preparation of Key intermediates (Compounds of interest) 5a-5c
Adding intermediate 4(110mg,0.30mmol,1eq.), the corresponding substituted aminophenylacetylene (42mg,0.36mmol,1.2eq.), sodium ascorbate (7.5mg,0.03mmol,0.1eq.), copper sulfate pentahydrate (17.8mg,0.09mmol,0.3eq.) to a mixed solvent of tetrahydrofuran and water (v/v ═ 1:1,6mL), stirring at room temperature, and monitoring by TLC; after the reaction was completed for 12 hours, 20mL of saturated sodium chloride solution was added to the reaction mixture, and the mixture was extracted with 20mL of dichloromethane, the organic phase was separated, dried over anhydrous sodium sulfate, filtered, the solvent was evaporated to dryness under reduced pressure, and separated by silica gel column chromatography (eluent EA: PE ═ 1:1) to obtain compounds 5a to 5 c.
Substituted aminophenylacetylene selected from 2-aminophenylacetylene and the intermediate 4 were reacted to give (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (5a)120mg as a white solid, yield 83%, melting point: 94-95 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ8.90(d,J=7.6Hz,1H,NH),8.33(s,1H,triazole-H),7.42(d,J=7.5Hz,1H,Ph-H),7.29–7.14(m,3H,Ph-H),7.14–6.98(m,3H,Ph-H),6.91(dd,J=16.8,7.5Hz,4H,Ph-H),6.76(d,J=8.1Hz,1H,Ph-H),6.59(t,J=7.3Hz,1H,Ph-H),6.16(s,2H,NH2),5.25–4.99(m,2H,triazoleCH2),4.46(q,J=8.1Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.2,4.7Hz,1H,PhCH),2.69(dd,J=13.1,9.4Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.40(C=O),159.02,147.54,145.05,137.68,135.78,129.33(2×C),129.10(2×C),128.88,128.70(2×C),127.93,127.03,123.22,116.40,116.25,115.10(2×C),113.02,55.85,52.10,51.85,37.87,37.77.ESI-MS:m/z485.5(M+1),507.4(M+23).C27H28N6O3[484.6].
substituted aminophenylacetylene selected from 3-aminophenylacetylene and the intermediate 4 were reacted to give (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (5b)126mg as a white solid, yield 87%, melting point: 90-91 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ8.88(d,J=7.8Hz,1H,NH),8.20(s,1H,triazole-H),7.29–7.14(m,3H,Ph-H),7.13–7.02(m,4H,Ph-H),6.91(dd,J=17.6,8.2Hz,5H,Ph-H),6.52(d,J=7.6Hz,1H,Ph-H),5.17(s,2H,PhNH2),5.13(d,J=16.4Hz,1H,triazoleCH),5.02(d,J=16.2Hz,1H,triazoleCH),4.45(q,J=8.2Hz,1H,CH),3.75(s,3H,OCH3),3.10(s,3H,NCH3),2.92(dd,J=13.4,4.8Hz,1H,PhCH),2.69(dd,J=13.2,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.20(C=O),165.53(C=O),159.01,149.51,147.15,137.69,135.79,131.59,129.81,129.33(2×C),129.11,128.71(2×C),127.03,122.90,115.09(2×C),113.97,113.36,110.80(2×C),55.85,52.10,51.73,37.85,37.77.ESI-MS:m/z 485.5(M+1),507.5(M+23).C27H28N6O3[484.6].
the substituted aminophenylacetylene is prepared by reacting 4-aminophenylacetylene with the intermediate 4 to obtain 70mg of (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (5c) as a white solid with a yield of 48%, a melting point: 105 ℃ and 106 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ8.86(d,J=7.8Hz,1H,NH),8.07(s,1H,triazole-H),7.47(d,J=8.4Hz,2H,Ph-H),7.27–7.13(m,3H,Ph-H),7.06(d,J=6.6Hz,2H,Ph-H),6.93(d,J=9.0Hz,2H,Ph-H),6.91–6.82(m,2H,Ph-H),6.60(d,J=8.4Hz,2H,Ph-H),5.23(s,2H,NH2),5.09(d,J=16.3Hz,1H,triazoleCH),4.98(d,J=16.3Hz,1H,triazoleCH),4.45(td,J=8.5,5.5Hz,1H,CH),3.75(s,3H,OCH3),3.10(s,3H,NCH3),2.91(dd,J=13.6,5.2Hz,1H,PhCH),2.68(dd,J=13.4,9.1Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.58(C=O),159.01,149.03,147.48,137.69,135.80,129.33(2×C),129.10(2×C),128.69(2×C),127.02,126.55(2×C),121.07,118.78,115.09(2×C),114.39(2×C),55.85,52.06,51.71,37.87,37.77.ESI-MS:m/z 485.5(M+1),507.4(M+23),523.5(M+39).C27H28N6O3[484.6].
example 5: preparation of target Compounds 6a- (1-12), 6b- (1-12), 6c- (1-12)
Adding the compounds 5a-5c (0.12g,0.25mmol,1eq.) and triethylamine (69 μ L,0.50mmol,2eq.) into 10mL of dichloromethane, slowly adding the corresponding acid chloride (0.37mmol,1.5eq.) thereto with stirring in an ice bath, then removing the ice bath and transferring to room temperature, and monitoring by TLC; after 10h, the reaction is finished, the solvent is evaporated under reduced pressure, then 10mL of saturated sodium chloride solution is added into the residue in the bottle, 10mL of dichloromethane is used for extraction, the water phase is extracted by dichloromethane (10mL multiplied by 3 times), the organic phases are combined and dried by anhydrous sodium sulfate, the filtration is carried out, the solvent is evaporated under reduced pressure, the crude target compound is obtained by silica gel column chromatography separation (eluent EA: PE ═ 1:1), and the pure target compounds 6a- (1-12), 6b- (1-12) and 6c- (1-12) are obtained by purification through silica gel preparation plates.
The corresponding acid chloride was reacted with (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (5a) using acetyl chloride (26. mu.L) to give (S) -2(2- (4- (2-acetylaminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (6a-1)61mg, white solid, yield 47%, melting point: 95-96 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.71(s,1H,PhNH),8.95(d,J=7.8Hz,1H,NH),8.47(s,1H,triazole-H),8.10(d,J=8.1Hz,1H,Ph-H),7.77(d,J=7.6Hz,1H,Ph-H),7.33(t,J=7.4Hz,1H,Ph-H),7.29–7.15(m,4H,Ph-H),7.14–7.01(m,2H,Ph-H),6.93(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.6Hz,2H,Ph-H),5.23(d,J=16.3Hz,1H,triazoleCH),5.12(d,J=16.3Hz,1H,triazoleCH),4.54–4.38(m,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.5,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.3Hz,1H,PhCH),2.12(s,3H,COCH3).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),168.89(C=O),165.29(C=O),159.03,145.45,137.66,135.86,135.78,129.32(2×C),129.10(2×C),128.77,128.71(2×C),128.07,127.04,125.03,124.76,123.43,120.94,115.09(2×C),55.86,52.15,51.94,37.85,37.77,24.89.ESI-MS:m/z 527.4(M+1),544.5(M+18),549.4(M+23),565.4(M+39).C29H30N6O4[526.6].
the corresponding acid chloride was selected from benzoyl chloride (43. mu.L) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to prepare (S) -N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-2)78mg, white solid, yield 53%, melting point: 103 ℃ and 104 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.11(s,1H,PhNH),8.98(d,J=7.8Hz,1H,NH),8.65(s,1H,triazole-H),8.61(d,J=8.3Hz,1H,Ph-H),8.06(d,J=7.0Hz,2H,Ph-HH),7.81(d,J=7.8Hz,1H,Ph-H),7.70–7.50(m,3H,Ph-H),7.41(t,J=7.8Hz,1H,Ph-H),7.30–7.14(m,4H,Ph-H),7.06(d,J=6.5Hz,2H,Ph-H),6.93(d,J=9.0Hz,2H,Ph-H),6.88(d,J=6.7Hz,2H,Ph-H),5.26(d,J=16.4Hz,1H,triazoleCH),5.15(d,J=16.4Hz,1H,triazoleCH),4.46(td,J=8.5,5.5Hz,1H,CH),3.74(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.4,5.0Hz,1H,PhCH),2.69(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.14(C=O),165.34(C=O),165.15(C=O),159.02,146.34,137.65,136.27,135.76,135.16,132.45,129.35(2×C),129.32(2×C),129.09(2×C),129.06,128.70(2×C),128.01,127.63(2×C),127.02,125.07,124.58,121.91,119.22,115.10(2×C),55.84,52.14,52.12,37.87,37.77.ESI-MS:m/z589.4(M+1),606.4(M+18),611.3(M+23),627.4(M+39).C34H32N6O4[588.7].
the corresponding acid chloride was selected from 4-methylbenzoyl chloride (49. mu.L) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to give (S) -N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) -4-methylbenzamide (6a-3)105mg, white solid, yield 70%, melting point: 118 ℃ and 119 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.07(s,1H,PhNH),8.99(d,J=7.8Hz,1H,NH),8.64(s,1H,triazole-H),8.61(d,J=8.3Hz,1H,Ph-H),7.96(d,J=8.1Hz,2H,Ph-H),7.80(d,J=7.7Hz,1H,Ph-H),7.40(t,J=6.7Hz,3H,Ph-H),7.20(tt,J=14.2,7.3Hz,4H,Ph-H),7.13–6.99(m,2H,Ph-H),6.93(d,J=8.9Hz,2H,Ph-H),6.88(d,J=6.8Hz,2H,Ph-H),5.26(d,J=16.4Hz,1H,triazoleCH),5.15(d,J=16.4Hz,1H,triazoleCH),4.61–4.34(m,1H,CH),3.74(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.4,5.0Hz,1H,PhCH),2.69(dd,J=13.4,9.2Hz,1H,PhCH),2.40(s,3H,PhCH3).13C NMR(100MHz,DMSO-d6)δ171.14(C=O),165.27(C=O),165.16(C=O),159.02,146.39,142.52,137.65,136.37,135.76,132.40,129.88(2×C),129.32(2×C),129.09(2×C),129.04,128.70(2×C),127.99,127.64(2×C),127.02,125.04,124.42,121.80,119.04,115.09(2×C),55.84,52.12,52.11,37.87,37.77,21.49.ESI-MS:m/z 603.4(M+1),620.5(M+18),625.4(M+23),641.3(M+39).C35H34N6O4[602.7].
the corresponding acid chloride was selected from 2-methoxybenzoyl chloride (67. mu.L) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to prepare 125mg of (S) -2-methoxy-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-4), white solid, yield 65%, melting point: 99-100 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ11.66(s,1H,PhNH),8.95(d,J=7.9Hz,1H,NH),8.55(d,J=8.3Hz,1H,Ph-H),8.47(s,1H,triazole-H),7.93(d,J=6.9Hz,1H,Ph-H),7.64(d,J=7.6Hz,1H,Ph-H),7.60–7.50(m,1H,Ph-H),7.40(t,J=7.8Hz,1H,Ph-H),7.28–7.13(m,5H,Ph-H),7.15–6.99(m,3H,Ph-H),6.93(d,J=8.9Hz,2H,Ph-H),6.88(d,J=6.6Hz,2H,Ph-H),5.23(d,J=16.3Hz,1H,triazoleCH),5.13(d,J=16.3Hz,1H,triazole-CH),4.47(td,J=8.5,5.4Hz,1H,CH),3.87(s,3H,OCH3),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.0Hz,1H,PhCH),2.69(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.16(C=O),165.27(C=O),164.08(C=O),159.02,157.36,145.64,137.66,136.09,135.77,133.66,131.58,129.32(2×C),129.10,128.89,128.82,128.69(2×C),127.02,125.08,124.45,123.07,122.82,121.13(2×C),120.14,115.10(2×C),112.51,56.29,55.85,52.12,51.97,37.85,37.77.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.4(M+23),657.4(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was selected from 3-methoxybenzoyl chloride (65. mu.L) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to prepare (S) -3-methoxy-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-5)150mg, white solid, yield 79%, melting point: 99-100 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.13(s,1H,PhNH),8.97(d,J=7.8Hz,1H,NH),8.65(s,1H,triazole-H),8.62(d,J=8.3Hz,1H,Ph-H),7.82(d,J=7.5Hz,1H,Ph-H),7.65(d,J=7.8Hz,1H,Ph-H),7.62(s,1H,Ph-H),7.51(t,J=7.9Hz,1H,Ph-H),7.42(t,J=7.6Hz,1H,Ph-H),7.21(dp,J=16.5,7.4Hz,5H,Ph-H),7.06(d,J=6.6Hz,2H,Ph-H),6.93(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.8Hz,2H,Ph-H),5.26(d,J=16.4Hz,1H,triazoleCH),5.16(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.5Hz,1H,CH),3.87(s,3H,OCH3),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.5,5.1Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.14(C=O),165.15(C=O),165.05(C=O),159.96,159.02,146.36,137.65,136.59,136.24,135.76,130.51,129.32(2×C),129.10(2×C),128.71(2×C),128.01,127.03,125.10,124.57,121.72,119.80(2×C),119.08,118.43,115.09(2×C),112.60,55.84,55.77(2×C),52.14,37.86,37.77.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.4(M+23),657.4(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was selected from 4-methoxybenzoyl chloride (79mg) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to prepare (S) -4-methoxy-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-6)130mg, white solid, yield 68%, melting point: 110-111 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.03(s,1H,PhNH),8.97(d,J=7.8Hz,1H,NH),8.64(s,1H,triazole-H),8.62(d,J=8.1Hz,1H,Ph-H),8.04(d,J=8.8Hz,2H,Ph-H),7.85–7.76(m,1H,Ph-H),7.45–7.36(m,1H,Ph-H),7.26–7.16(m,4H,Ph-H),7.14(d,J=8.9Hz,2H,Ph-H),7.06(d,J=6.8Hz,2H,Ph-H),6.93(d,J=9.0Hz,2H,Ph-H),6.89(d,J=6.6Hz,2H,Ph-H),5.26(d,J=16.4Hz,1H,triazoleCH),5.16(d,J=16.4Hz,1H,triazoleCH),4.47(td,J=8.5,5.3Hz,1H,CH),3.86(s,3H,OCH3),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.1Hz,1H,PhCH),2.70(dd,J=13.5,9.1Hz,1H,PhCH).13CNMR(100MHz,DMSO-d6)δ171.15(C=O),165.18(C=O),164.85(C=O),162.62,159.02,146.45,137.66,136.51,135.76,129.53(2×C),129.32(2×C),129.10(2×C),129.04,128.71(2×C),127.96,127.26,127.03,125.04,124.25,121.69,118.87,115.09(2×C),114.59(2×C),55.95,55.84,52.16,52.11,37.85,37.77.ESI-MS:m/z 619.5(M+1),641.3(M+23).C35H34N6O5[618.7].
the corresponding acid chloride was selected from methyl 4-carboxylate benzoyl chloride (74mg) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to prepare (S) -methyl 4- ((2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2- (methyl) oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) carbamoyl) benzoate (6a-7)121mg, white solid, yield 76%, melting point: 130 ℃ and 131 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.04(s,1H,PhNH),8.95(d,J=7.8Hz,1H,NH),8.61(s,1H,triazole-H),8.50(d,J=8.2Hz,1H,Ph-H),8.22–8.10(m,4H,Ph-H),7.83(d,J=7.2Hz,1H,Ph-H),7.43(t,J=7.4Hz,1H,Ph-H),7.28(t,J=7.5Hz,1H,Ph-H),7.19(q,J=8.7,7.5Hz,3H,Ph-H),7.06(d,J=7.4Hz,2H,Ph-H),6.92(d,J=8.9Hz,2H,Ph-H),6.88(d,J=6.6Hz,2H,Ph-H),5.25(d,J=16.3Hz,1H,triazoleCH),5.15(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.5,5.5Hz,1H,CH),3.90(s,3H,COOCH3),3.74(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.1Hz,1H,PhCH),2.69(dd,J=13.4,9.1Hz,1H,PhCH).13CNMR(100MHz,DMSO-d6)δ171.12(C=O),166.06(C=O),165.14(C=O),164.61(C=O),159.03,146.07,139.27,137.64(2×C),135.89(2×C),135.78,132.84,130.05(2×C),129.32(2×C),129.06(2×C),128.69(2×C),128.09(2×C),127.00,125.08(2×C),122.58,120.11,115.10(2×C),55.84(2×C),52.91,52.12,37.91,37.76.ESI-MS:m/z647.5(M+1),664.5(M+18),669.4(M+23),685.5(M+39).C35H34N6O5[646.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) using 4-cyanobenzoyl chloride (62mg) to give (S) -4-cyano-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-8)93mg, white solid, yield 61%, melting point: 142 ℃ and 143 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.04(s,1H,PhNH),8.95(d,J=7.8Hz,1H,NH),8.61(s,1H,triazole-H),8.47(d,J=8.2Hz,1H,Ph-H),8.18(d,J=8.2Hz,2H,Ph-H),8.07(d,J=8.3Hz,2H,Ph-H),7.83(d,J=7.7Hz,1H,Ph-H),7.43(t,J=7.7Hz,1H,Ph-H),7.28(t,J=7.5Hz,1H,Ph-H),7.20(q,J=8.8,7.6Hz,3H,Ph-H),7.06(d,J=7.3Hz,2H,Ph-H),6.92(d,J=8.8Hz,2H,Ph-H),6.88(d,J=6.8Hz,2H,Ph-H),5.25(d,J=16.3Hz,1H,triazoleCH),5.15(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.4Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.0Hz,1H,PhCH),2.69(dd,J=13.3,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.14(C=O),165.17(C=O),164.02(C=O),159.04,146.01,139.17,137.65,135.78,135.71,133.36(2×C),129.31(2×C),129.07(2×C),128.70(2×C),128.53(2×C),128.12,127.02,125.28,125.12,122.71,120.32,118.69(2×C),115.11(2×C),114.68,55.85,52.16,52.10,37.90,37.77.ESI-MS:m/z614.3(M+1),631.4(M+18),636.4(M+23),652.5(M+39).C35H31N7O4[613.7].
the corresponding acid chloride was selected from 2-fluorobenzoyl chloride (44. mu.L) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to give (S) -2-fluoro-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-9)114mg, white solid, yield 76%, melting point: 105 ℃ and 106 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ11.76(s,1H,PhNH),8.95(d,J=7.9Hz,1H,NH),8.58(s,1H,triazole-H),8.48(d,J=8.1Hz,1H,Ph-H),7.87(t,J=7.1Hz,1H,Ph-H),7.78(d,J=7.7Hz,1H,Ph-H),7.64(q,J=6.0Hz,1H,Ph-H),7.50–7.33(m,3H,Ph-H),7.27(t,J=7.5Hz,1H,Ph-H),7.19(q,J=8.3,7.3Hz,3H,Ph-H),7.11–6.99(m,2H,Ph-H),6.93(d,J=9.0Hz,2H,Ph-H),6.88(d,J=6.5Hz,2H,Ph-H),5.22(d,J=16.4Hz,1H,triazoleCH),5.12(d,J=16.3Hz,1H,triazoleCH),4.46(td,J=8.5,5.4Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.0Hz,1H,PhCH),2.69(dd,J=13.4,9.1Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.13(C=O),165.14(C=O),162.58(C=O),159.69(d,1JCF=248.4Hz),159.02,145.90,137.64,135.72(d,3JCF=9.7Hz),133.94(d,3JCF=8.6Hz),130.84(d,4JCF=2.1Hz),129.32(2×C),129.08(2×C),128.99,128.69(2×C),128.21,127.01,125.41(d,4JCF=3.4Hz),125.07,124.98,124.13(d,2JCF=13.4Hz),122.63,119.87,117.13,116.90,115.10(2×C),55.84,52.11,52.03,37.89,37.77.ESI-MS:m/z 607.4(M+1),624.5(M+18),645.5(M+39).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 3-fluorobenzoyl chloride (45. mu.L) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino ] -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to give (S) -3-fluoro-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-10)88mg, white solid, yield 59%, melting point: 109 ℃ and 110 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.06(s,1H,PhNH),8.97(d,J=7.8Hz,1H,NH),8.64(s,1H,triazole-H),8.52(d,J=8.2Hz,1H,Ph-H),7.91(d,J=7.7Hz,1H,Ph-H),7.83(t,J=7.8Hz,2H,Ph-H),7.66(q,J=7.8Hz,1H,Ph-H),7.51(dt,J=8.3,4.4Hz,1H,Ph-H),7.42(t,J=7.6Hz,1H,Ph-H),7.27(t,J=7.5Hz,1H,Ph-H),7.20(q,J=9.3,7.8Hz,3H,Ph-H),7.13–6.99(m,2H,Ph-H),6.93(d,J=8.8Hz,2H,Ph-H),6.89(d,J=6.8Hz,2H,Ph-H),5.26(d,J=16.4Hz,1H,triazoleCH),5.16(d,J=16.3Hz,1H,triazoleCH),4.47(q,J=8.3Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.3,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.13(C=O),165.16(C=O),164.02(d,4JCF=2.3Hz,C=O),162.67(d,1JCF=243.5Hz),159.02,146.17,137.65(2×C),137.58(d,3JCF=6.7Hz),135.92,135.76,131.56(d,3JCF=7.7Hz),129.32(2×C),129.08(2×C),128.70(2×C),128.05,127.01,125.10,124.96,123.69(d,4JCF=2.3Hz),122.32,119.78,119.37(d,2JCF=20.8Hz),115.09(2×C),114.63(d,2JCF=22.8Hz),55.84,52.13,52.11,37.88,37.76.ESI-MS:m/z 607.4(M+1),624.4(M+18),629.4(M+23),645.4(M+39).C34H31FN6O4[606.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) using 4-fluorobenzoyl chloride (44. mu.L) to give (S) -4-fluoro-N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6a-11)101mg, white solid, yield 67%, melting point: 123 ℃ and 124 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.01(s,1H,PhNH),8.97(d,J=7.8Hz,1H,NH),8.63(s,1H,triazole-H),8.54(d,J=8.2Hz,1H,Ph-H),8.12(dd,J=8.7,5.5Hz,2H,Ph-H),7.88–7.78(m,1H,Ph-H),7.43(q,J=8.3,7.7Hz,3H,Ph-H),7.32–7.23(m,1H,Ph-H),7.23–7.15(m,3H,Ph-H),7.06(d,J=6.8Hz,2H,Ph-H),6.93(d,J=9.0Hz,2H,Ph-H),6.88(d,J=6.7Hz,2H,Ph-H),5.26(d,J=16.4Hz,1H,triazoleCH),5.15(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.5,5.4Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.69(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.15(C=O),165.18(C=O),164.72(d,1JCF=243.5Hz),164.32(C=O),159.03,146.23,137.65,136.12,135.76,131.67(d,4JCF=2.3Hz),130.41,130.32,129.31(2×C),129.09,129.04,128.70(2×C),128.03,127.02,125.08,124.74,122.22,119.61,116.44(2×C),116.22,115.09(2×C),55.84,52.16,52.09,37.86,37.76.ESI-MS:m/z 607.4(M+1),624.4(M+18),629.4(M+23),645.4(M+39).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 4-phenylbenzoyl chloride (81mg) and (S) -2(2- (4- (2-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5a) to give (S) -N- (2- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) - [1,1' -Biphenyl ] -4-carboxamide (6a-12)95mg, white solid, yield 58%, melting point: 120 ℃ and 121 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.16(s,1H,PhNH),8.98(d,J=7.8Hz,1H,NH),8.67(s,1H,triazole-H),8.63(d,J=8.3Hz,1H,Ph-H),8.16(d,J=8.2Hz,2H,Ph-H),7.91(d,J=8.2Hz,2H,Ph-H),7.83(d,J=7.7Hz,1H,Ph-H),7.79(d,J=7.6Hz,2H,Ph-H),7.52(t,J=7.5Hz,2H,Ph-H),7.30–7.15(m,5H,Ph-H),7.11–7.04(m,2H,Ph-H),6.95–6.85(m,5H,Ph-H),5.27(d,J=16.4Hz,1H,triazoleCH),5.18(d,J=13.5Hz,1H,triazoleCH),4.51–4.42(m,1H,CH),3.73(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.3,9.3Hz,1H,PhCH).13C NMR(101MHz,DMSO-d6)δ171.15(C=O),165.18(C=O),165.00(C=O),159.02,146.36,146.05,143.92,139.41,137.65,136.30,135.76,133.90,129.54(2×C),129.32(2×C),129.09(2×C),128.70(2×C),128.34(2×C),127.53(2×C),127.42(2×C),127.02,125.10,124.60,132.22,121.99,119.27,116.26,115.09(2×C),55.83,52.15,52.11,37.87,37.76.ESI-MS:m/z 665.4(M+1),682.5(M+18).C40H36N6O4[664.8].
the corresponding acid chloride was reacted with (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (5b) using acetyl chloride (26. mu.L) to give (S) -2- (2- (4- (3-acetylaminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (6b-1)68mg, white solid, yield 52%, melting point: 206- & lt207 & gt.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.05(s,1H,PhNH),8.91(d,J=7.8Hz,1H,NH),8.34(s,1H,triazole-H),8.12(s,1H,Ph-H),7.56(d,J=8.0Hz,1H,Ph-H),7.45(d,J=7.7Hz,1H,Ph-H),7.36(t,J=7.9Hz,1H,Ph-H),7.27–7.14(m,3H,Ph-H),7.14–7.00(m,2H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.4Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.46(td,J=8.5,5.4Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.0Hz,1H,PhCH),2.70(dd,J=13.5,9.2Hz,1H,PhCH),2.07(s,3H,COCH3).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),168.87(C=O),165.46,159.02,146.43,140.33,137.67,135.79,131.54,129.75,129.33(2×C),129.10,128.70(2×C),127.03,123.36(2×C),120.40,118.85,115.92,115.10(2×C),55.85,52.09,51.80,37.88,37.77,24.53.ESI-MS:m/z 527.4(M+1),544.5(M+18),549.4(M+23),565.5(M+39).C29H30N6O4[526.6].
the corresponding acid chloride was selected from benzoyl chloride (43. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to prepare (S) -N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-2)106mg, white solid, yield 73%, melting point: 135 ℃ and 136 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.38(s,1H,PhNH),8.93(d,J=7.8Hz,1H,NH),8.37(s,1H,Ph-H),8.34(s,1H,triazole-H),8.00(d,J=7.1Hz,2H,Ph-H),7.78(d,J=8.0Hz,1H,Ph-H),7.62-7.52(m,4H,Ph-H),7.42(t,J=7.9Hz,1H,Ph-H),7.23-7.18(m,3H,Ph-H),7.08–7.06(m,2H,Ph-H),6.95-6.88(m,4H,Ph-H),5.18(d,J=16.3Hz,1H,triazoleCH),5.07(d,J=16.3Hz,1H,triazoleCH),4.46(td,J=8.5,5.5Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.4,5.0Hz,1H,PhCH),2.69(dd,J=13.5,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),166.06(C=O),165.48(C=O),159.02,146.45,140.20,137.68,135.79,135.30,132.10,131.52,129.70,129.34(2×C),129.11,128.87(2×C),128.71(2×C),128.16(2×C),127.04,123.43(2×C),121.04,120.22,117.40,115.10(2×C),55.85,52.11,51.82,37.87,37.78.ESI-MS:m/z 589.5(M+1),606.4(M+18),611.4(M+23),627.4(M+39).C34H32N6O4[588.7].
the corresponding acid chloride was selected from 4-methylbenzoyl chloride (49. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to give (S) -N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) -4-methylbenzamide (6b-3)94mg, white solid, yield 63%, melting point: 212 ℃ and 213 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.28(s,1H,PhNH),8.92(d,J=7.8Hz,1H,NH),8.37(s,1H,Ph-H),8.34(s,1H,triazole-H),7.92(d,J=8.0Hz,2H,Ph-H),7.78(d,J=7.9Hz,1H,Ph-H),7.53(d,J=7.7Hz,1H,Ph-H),7.42(t,J=7.9Hz,1H,Ph-H),7.35(d,J=8.0Hz,2H,Ph-H),7.21(q,J=7.9,7.0Hz,3H,Ph-H),7.15–7.01(m,2H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.90(d,J=6.6Hz,2H,Ph-H),5.18(d,J=16.3Hz,1H,triazoleCH),5.07(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.3Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH),2.40(s,3H,PhCH3).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.85(C=O),165.48(C=O),159.02,146.47,142.11,140.27,137.68,135.79,132.40,131.49,129.67,129.39(2×C),129.34(2×C),129.12,128.71(2×C),128.19(2×C),127.04,123.41(2×C),120.92,120.21,117.39,115.10(2×C),55.85,52.10,51.81,37.87,37.78,21.50.ESI-MS:m/z603.4(M+1),620.5(M+18),625.4(M+23),641.3(M+39).C35H34N6O4[602.7].
the corresponding acid chloride was selected from 2-methoxybenzoyl chloride (54. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to give (S) -2-methoxy-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-4)99mg, white solid, yield 65%, melting point: 125 ℃ and 126 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.23(s,1H,PhNH),8.93(d,J=7.8Hz,1H,NH),8.37(s,1H,Ph-H),8.29(s,1H,triazole-H),7.68(dd,J=11.9,8.0Hz,2H,Ph-H),7.52(t,J=9.4Hz,2H,Ph-H),7.41(t,J=7.9Hz,1H,Ph-H),7.30–7.15(m,4H,Ph-H),7.08(t,J=7.3Hz,3H,Ph-H),6.94(d,J=8.8Hz,2H,Ph-H),6.90(d,J=6.6Hz,2H,Ph-H),5.18(d,J=16.3Hz,1H,triazoleCH),5.07(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.4Hz,1H,CH),3.92(s,3H,OCH3),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.46(C=O),165.10(C=O),159.02,156.96,146.43,140.06,137.68,135.79,132.52,131.62,130.13,129.76,129.34(2×C),129.11,128.71(2×C),127.03,125.41,123.45,120.95(2×C),120.88,119.65,116.75,115.10(2×C),112.46,56.37,55.85,52.10,51.83,37.89,37.77.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.3(M+23),657.3(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was selected from 3-methoxybenzoyl chloride (54. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to prepare 73mg of (S) -3-methoxy-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-5), white solid, yield 48%, melting point: 115 ℃ and 116 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.34(s,1H,PhNH),8.92(d,J=7.6Hz,1H,NH),8.37(s,1H,Ph-H),8.33(s,1H,triazole-H),7.79(d,J=7.7Hz,1H,Ph-H),7.59(d,J=7.5Hz,1H,Ph-H),7.54(s,2H,Ph-H),7.45(dt,J=13.0,7.9Hz,2H,Ph-H),7.29–7.13(m,4H,Ph-H),7.08(d,J=6.6Hz,2H,Ph-H),6.94(d,J=8.5Hz,2H,Ph-H),6.90(d,J=6.5Hz,2H,Ph-H),5.19(d,J=16.3Hz,1H,triazoleCH),5.08(d,J=16.3Hz,1H,triazoleCH),4.48(q,J=7.9Hz,1H,CH),3.86(s,3H,OCH3),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.2,4.6Hz,1H,PhCH),2.71(dd,J=13.0,9.4Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.75(C=O),165.47(C=O),159.65,159.02,146.44,140.12,137.68,136.68,135.79,131.52,130.03,129.69,129.34(2×C),129.10,128.71(2×C),127.03,123.42,121.09,120.38(2×C),120.31,117.87,117.49,115.11(2×C),113.36,55.85,55.82,52.10,51.83,37.89,37.78.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.3(M+23),657.5(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) using 4-methoxybenzoyl chloride (63mg) to give (S) -4-methoxy-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-6)97mg, white solid, yield 63%, melting point: 199 ℃ and 200 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.20(s,1H,PhNH),8.91(d,J=7.8Hz,1H,NH),8.36(s,1H,Ph-H),8.32(s,1H,triazole-H),8.01(d,J=8.7Hz,2H,Ph-H),7.78(d,J=8.1Hz,1H,Ph-H),7.52(d,J=7.7Hz,1H,Ph-H),7.41(t,J=7.9Hz,1H,Ph-H),7.26–7.16(m,3H,Ph-H),7.08(d,J=8.7Hz,4H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.6Hz,2H,Ph-H),5.18(d,J=16.3Hz,1H,triazoleCH),5.07(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.6Hz,1H,CH),3.85(s,3H,OCH3),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.5,5.1Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.47(C=O),165.40(C=O),162.40,159.02,146.50,140.37,137.68,135.79,131.47,130.10(2×C),129.63,129.34(2×C),129.11,128.71(2×C),127.30,127.03,123.38(2×C),120.80,120.19,117.38,115.11(2×C),114.08(2×C),55.91,55.85,52.10,51.83,37.89,37.78.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.4(M+23),657.5(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was selected from methyl 4-carboxylate benzoyl chloride (74mg) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to prepare methyl (S) -4- ((3- (1- (2-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2- (methyl) oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) carbamoyl) benzoate (6b-7)94mg, white solid, yield 58%, melting point: 153-.
Spectral data:1H NMR(400MHz,DMSO-d6)δ12.04(s,1H,PhNH),8.95(d,J=7.8Hz,1H,NH),8.61(s,1H,triazole-H),8.49(d,J=8.2Hz,1H,Ph-H),8.21–8.09(m,4H,Ph-H),7.83(d,J=7.4Hz,1H,Ph-H),7.43(t,J=7.5Hz,1H,Ph-H),7.28(t,J=7.5Hz,1H,Ph-H),7.19(q,J=8.7,7.5Hz,3H,Ph-H),7.06(d,J=6.9Hz,2H,Ph-H),6.92(d,J=8.9Hz,2H,Ph-H),6.88(d,J=6.7Hz,2H,Ph-H),5.25(d,J=16.3Hz,1H,triazoleCH),5.15(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.6Hz,1H,CH),3.90(s,3H,COOCH3),3.74(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.0Hz,1H,PhCH),2.69(dd,J=13.4,9.1Hz,1H,PhCH).13CNMR(100MHz,DMSO-d6)δ171.13(C=O),166.05(C=O),165.16(C=O),164.61(C=O),159.02,146.05,139.26,137.65,135.86,135.76,132.82,130.06(2×C),129.31(2×C),129.07(2×C),128.70(2×C),128.11(2×C),127.01(2×C),125.11(2×C),122.60(2×C),120.12,115.09(2×C),55.84,52.94,52.14,52.08,37.86,37.76.ESI-MS:m/z 647.4(M+1),664.4(M+18),669.4(M+23),685.5(M+39).C36H34N6O6[646.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) using 4-cyanobenzoyl chloride (62mg) to give (S) -4-cyano-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-8)55mg, white solid, yield 36%, melting point: 224-225 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.61(s,1H,PhNH),8.93(d,J=7.8Hz,1H,NH),8.39(s,1H,Ph-H),8.34(s,1H,triazole-H),8.15(d,J=8.3Hz,2H,Ph-H),8.05(d,J=8.3Hz,2H,Ph-H),7.78(d,J=8.1Hz,1H,Ph-H),7.57(d,J=7.7Hz,1H,Ph-H),7.45(t,J=7.9Hz,1H,Ph-H),7.21(q,J=7.8,7.0Hz,3H,Ph-H),7.13–7.02(m,2H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.6Hz,2H,Ph-H),5.19(d,J=16.3Hz,1H,triazoleCH),5.08(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.5,5.1Hz,1H,CH),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13CNMR(100MHz,DMSO-d6)δ171.19(C=O),165.46(C=O),164.67(C=O),159.02,146.33,139.79,139.31,137.68,135.79,132.95(2×C),131.61,129.81,129.33(2×C),129.11,129.03(2×C),128.71(2×C),127.03,123.48(2×C),121.47,120.27,118.80,117.43,115.10(2×C),114.36,55.85,52.11,51.83,37.88,37.77.ESI-MS:m/z 614.3(M+1),631.5(M+18),636.3(M+23),652.4(M+39).C35H31N7O4[613.7].
the corresponding acid chloride was selected from 2-fluorobenzoyl chloride (44. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to give (S) -2-fluoro-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-9)92mg, white solid, yield 61%, melting point: 114-.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.55(s,1H,PhNH),8.93(d,J=7.9Hz,1H,NH),8.38(s,1H,Ph-H),8.30(s,1H,triazole-H),7.70(t,J=7.7Hz,2H,Ph-H),7.65–7.57(m,1H,Ph-H),7.55(d,J=7.8Hz,1H,Ph-H),7.43(t,J=7.9Hz,1H,Ph-H),7.36(q,J=9.0,7.4Hz,2H,Ph-H),7.26–7.16(m,3H,Ph-H),7.14–7.01(m,2H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.90(d,J=6.4Hz,2H,Ph-H),5.18(d,J=16.3Hz,1H,triazoleCH),5.07(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.5Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.46(C=O),163.35(C=O),159.36(d,1JCF=247.0Hz),159.02,146.34,139.88,137.68,135.79,133.02(d,3JCF=8.4Hz),131.67,130.38(d,4JCF=2.7Hz),129.86,129.34(2×C),129.11,128.71(2×C),127.03,125.44(d,2JCF=15.0Hz),125.04(d,4JCF=3.4Hz),123.47,121.25,119.63,116.75(2×C),116.53,115.10(2×C),55.85,52.10,51.82,37.88,37.77.ESI-MS:m/z 607.4(M+1),624.4(M+18),629.4(M+23),645.4(M+39).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 3-fluorobenzoyl chloride (45. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to give (S) -3-fluoro-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-10)112mg, white solid, yield 75%, melting point: 167 ℃ and 168 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.44(s,1H,PhNH),8.93(d,J=7.8Hz,1H,NH),8.39(s,1H,Ph-H),8.34(s,1H,triazole-H),7.83(dt,J=24.4,8.0Hz,3H,Ph-H),7.61(q,J=7.9Hz,1H,Ph-H),7.56(d,J=7.7Hz,1H,Ph-H),7.46(dt,J=16.2,7.3Hz,2H,Ph-H),7.29–7.15(m,3H,Ph-H),7.15–7.01(m,2H,Ph-H),6.94(d,J=8.8Hz,2H,Ph-H),6.90(d,J=6.5Hz,2H,Ph-H),5.19(d,J=16.3Hz,1H,triazoleCH),5.08(d,J=16.3Hz,1H,triazoleCH),4.54–4.41(m,1H,CH),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.47(C=O),164.64(d,4JCF=2.4Hz,C=O),162.39(d,1JCF=242.7Hz),159.02,146.39,139.92,137.68,137.57(d,3JCF=6.8Hz),135.79,131.56,131.11,131.03,129.75,129.34(2×C),129.11,128.71(2×C),127.03,124.40(d,4JCF=2.6Hz),123.45,121.28,120.28,119.01(d,2JCF=21.4Hz),117.46,115.10(2×C),114.88,55.85,52.11,51.83,37.88,37.77.ESI-MS:m/z 607.4(M+1),624.4(M+18),629.4(M+23),645.4(M+39).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 4-fluorobenzoyl chloride (44. mu.L) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to give (S) -4-fluoro-N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6b-11)45mg, white solid, yield 30%, melting point: 173 ℃ and 174 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.44(s,1H,PhNH),8.95(d,J=7.8Hz,1H,NH),8.37(s,1H,Ph-H),8.34(s,1H,triazole-H),8.11(dd,J=8.1,5.7Hz,2H,Ph-H),7.79(d,J=7.8Hz,1H,Ph-H),7.53(d,J=7.6Hz,1H,Ph-H),7.48–7.31(m,3H,Ph-H),7.21(q,J=7.2,6.4Hz,3H,Ph-H),7.12–6.99(m,2H,Ph-H),6.94(d,J=8.7Hz,2H,Ph-H),6.90(d,J=6.7Hz,2H,Ph-H),5.19(d,J=16.3Hz,1H,triazoleCH),5.08(d,J=16.2Hz,1H,triazoleCH),4.46(q,J=8.1Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,4.8Hz,1H,PhCH),2.70(dd,J=13.3,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.17(C=O),165.47(C=O),165.00(d,1JCF=245.0Hz),164.93(C=O),159.02,146.43,140.13,137.71,135.82,130.99(2×C),130.90,129.67,129.35(2×C),129.10,128.69(2×C),127.01,123.40,121.09,120.31,117.50,115.89(2×C),115.67(2×C),115.11(2×C),55.87,52.13,51.85,37.88,37.78.ESI-MS:m/z 607.4(M+1),624.4(M+18),629.4(M+23),645.3(M+39).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 4-phenylbenzoyl chloride (81mg) and (S) -2(2- (4- (3-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5b) to give (S) -N- (3- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) - [1,1' -Biphenyl ] -4-carboxamide (6b-12)96mg, white solid, yield 58%, melting point: 170 ℃ and 171 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.43(s,1H,PhNH),8.94(d,J=7.8Hz,1H,NH),8.39(s,1H,Ph-H),8.38(s,1H,triazole-H),8.12(d,J=8.2Hz,2H,Ph-H),7.86(d,J=8.3Hz,2H,Ph-H),7.82(d,J=8.4Hz,1H,Ph-H),7.78(d,J=7.6Hz,2H,Ph-H),7.53(q,J=7.4Hz,3H,Ph-H),7.44(dt,J=7.8,4.3Hz,2H,Ph-H),7.22(q,J=7.8,7.0Hz,3H,Ph-H),7.14–7.01(m,2H,Ph-H),6.95(d,J=8.8Hz,2H,Ph-H),6.90(d,J=6.6Hz,2H,Ph-H),5.19(d,J=16.3Hz,1H,triazoleCH),5.08(d,J=16.3Hz,1H,triazoleCH),4.47(q,J=8.4Hz,1H,CH),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.71(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.66(C=O),165.48(C=O),159.02,146.47,143.62,140.23,139.57,137.69,135.79,134.03,131.54,129.71,129.54(2×C),129.34(2×C),129.11(2×C),128.88(2×C),128.71(2×C),128.63,127.40(2×C),127.07(2×C),123.43(2×C),121.05,120.24,117.41,115.11(2×C),55.85,52.11,51.83,37.88,37.78.ESI-MS:m/z665.4(M+1),682.5(M+18),687.4(M+23).C40H36N6O4[664.8].
the corresponding acid chloride was reacted with (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (5c) using acetyl chloride (26. mu.L) to give (S) -2- (2- (4- (4-acetylaminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (6c-1)61mg, white solid, yield 47%, melting point: 134 ℃ and 135 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.04(s,1H,PhNH),8.89(d,J=7.8Hz,1H,NH),8.30(s,1H,triazole-H),7.75(d,J=8.5Hz,2H,Ph-H),7.65(d,J=8.5Hz,2H,Ph-H),7.21(q,J=7.2,6.7Hz,3H,Ph-H),7.06(d,J=6.6Hz,2H,Ph-H),6.93(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.5Hz,2H,Ph-H),5.15(d,J=16.4Hz,1H,triazoleCH),5.04(d,J=16.3Hz,1H,triazoleCH),4.46(q,J=8.3Hz,1H,CH),3.75(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.5,5.0Hz,1H,PhCH),2.69(dd,J=13.3,9.2Hz,1H,PhCH),2.06(s,3H,COCH3).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),168.78(C=O),165.48(C=O),159.02,146.40,139.44,137.68,135.80,129.33(2×C),129.10,128.70(2×C),127.02,125.97(2×C),125.89,122.70(2×C),119.67(2×C),115.10(2×C),55.85,52.09,51.80,37.89,37.77,24.51.ESI-MS:m/z 527.4(M+1),544.5(M+18),549.4(M+23),565.4(M+39).C29H30N6O4[526.6].
the corresponding acid chloride was selected from benzoyl chloride (43. mu.L) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to prepare (S) -N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-2)70mg, white solid, yield 48%, melting point: 171 ℃ and 172 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H,PhNH),8.91(d,J=7.8Hz,1H,NH),8.35(s,1H,triazole-H),7.98(d,J=7.2Hz,2H,Ph-H),7.89(d,J=8.7Hz,2H,Ph-H),7.83(d,J=8.6Hz,2H,Ph-H),7.61(t,J=7.2Hz,1H,Ph-H),7.55(t,J=7.3Hz,2H,Ph-H),7.22(q,J=7.3,6.7Hz,3H,Ph-H),7.07(d,J=6.5Hz,2H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.90(d,J=6.5Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.4,5.6Hz,1H,CH),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,5.1Hz,1H,PhCH),2.71(dd,J=13.6,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),166.03(C=O),165.49(C=O),159.03,145.38,139.29,137.69,135.80,135.39,132.06,129.34(2×C),129.10(2×C),128.86(2×C),128.71(2×C),128.13(2×C),127.03,126.53,125.87(2×C),122.87,121.05(2×C),115.11(2×C),55.86,52.09,51.83,37.90,37.78.ESI-MS:m/z 589.4(M+1),606.4(M+18),611.3(M+23),627.4(M+39).C34H32N6O4[588.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) using 4-methylbenzoyl chloride (49. mu.L) to give (S) -N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) -4-methylbenzamide (6c-3)72mg, white solid, yield 48%, melting point: 138 ℃ and 139 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.27(s,1H,PhNH),8.91(d,J=7.7Hz,1H,NH),8.35(s,1H,triazole-H),7.99–7.85(m,4H,Ph-H),7.82(d,J=8.3Hz,2H,Ph-H),7.35(d,J=7.6Hz,2H,Ph-H),7.22(q,J=8.0,6.9Hz,3H,Ph-H),7.07(d,J=7.0Hz,2H,Ph-H),6.94(d,J=8.4Hz,2H,Ph-H),6.90(d,J=6.4Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.47(q,J=7.7Hz,1H,CH),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.2,4.5Hz,1H,PhCH),2.76–2.64(m,1H,PhCH),2.40(s,3H,PhCH3).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.82(C=O),165.49(C=O),159.02,146.40,142.08,139.36,137.68,135.80,132.48,129.38(2×C),129.34(2×C),129.10(2×C),128.70(2×C),128.17(2×C),127.03,126.42,125.85(2×C),122.84,121.03(2×C),115.10(2×C),55.86,52.09,51.83,37.90,37.78,21.49.ESI-MS:m/z603.4(M+1),620.5(M+18),625.5(M+23),641.4(M+39).C35H34N6O4[602.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) using 2-methoxybenzoyl chloride (54. mu.L) to give (S) -2-methoxy-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-4)53mg, white solid, yield 34%, melting point: 146 ℃ and 147 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.23(s,1H,PhNH),8.91(d,J=7.7Hz,1H,NH),8.35(s,1H,triazole-H),7.92–7.77(m,4H,Ph-H),7.66(d,J=7.3Hz,1H,Ph-H),7.52(t,J=7.6Hz,1H,Ph-H),7.21(t,J=8.2Hz,4H,Ph-H),7.08(t,J=7.2Hz,3H,Ph-H),6.94(d,J=8.6Hz,2H,Ph-H),6.90(d,J=6.7Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.47(q,J=8.2Hz,1H,CH),3.92(s,3H,OCH3),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,4.9Hz,1H,PhCH),2.71(dd,J=13.4,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.49(C=O),164.97(C=O),159.03,156.95,146.38,139.15,137.69,135.81,132.52,130.13,129.34(2×C),129.10,128.70(2×C),127.03,126.39,125.96(2×C),125.39,122.83,120.96(2×C),120.42(2×C),115.11(2×C),112.47,56.37,55.86,52.09,51.82,37.91,37.78.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.4(M+23).C35H34N6O5[618.7].
the corresponding acid chloride was selected from 3-methoxybenzoyl chloride (54. mu.L) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to prepare 80mg of (S) -3-methoxy-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-5), white solid, yield 52%, melting point: 141 ℃ and 142 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.32(s,1H,PhNH),8.91(d,J=7.8Hz,1H,NH),8.35(s,1H,triazole-H),7.87(d,J=8.7Hz,2H,Ph-H),7.83(d,J=8.7Hz,2H,Ph-H),7.56(d,J=7.6Hz,1H,Ph-H),7.51(s,1H,Ph-H),7.46(t,J=7.9Hz,1H,Ph-H),7.26–7.15(m,4H,Ph-H),7.07(d,J=6.5Hz,2H,Ph-H),6.94(d,J=8.8Hz,2H,Ph-H),6.90(d,J=6.5Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.47(q,J=8.3Hz,1H,CH),3.85(s,3H,OCH3),3.76(s,3H,OCH3),3.12(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.74(C=O),165.48(C=O),159.65,159.03,146.38,139.20,137.68,136.79,135.81,130.03,129.34(2×C),129.10,128.70(2×C),127.02,126.58,125.86(2×C),122.87,121.13(2×C),120.35(2×C),117.81,115.11(2×C),113.39,55.82(2×C),52.09,51.84,37.91,37.78.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.3(M+23),657.4(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) using 4-methoxybenzoyl chloride (63mg) to give (S) -4-methoxy-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-6)85mg, white solid, yield 55%, melting point: 141 ℃ and 142 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.20(s,1H,PhNH),8.92(d,J=7.1Hz,1H,NH),8.34(s,1H,triazole-H),7.98(d,J=7.8Hz,2H,Ph-H),7.86(d,J=7.5Hz,2H,Ph-H),7.81(d,J=7.6Hz,2H,Ph-H),7.26–7.15(m,3H,Ph-H),7.08(d,J=7.2Hz,4H,Ph-H),6.94(d,J=8.1Hz,2H,Ph-H),6.89(d,J=6.0Hz,2H,Ph-H),5.16(d,J=16.1Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.46(q,J=8.5Hz,1H,CH),3.85(s,3H,OCH3),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.99–2.87(m,1H,PhCH),2.76–2.62(m,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.50(C=O),165.36(C=O),162.39,159.02,146.42,139.47,137.69,135.80,130.08(2×C),129.34(2×C),129.11(2×C),128.71(2×C),127.37,127.03,126.29,125.83(2×C),122.82,120.99(2×C),115.10(2×C),114.08(2×C),55.91,55.85,52.10,51.82,37.88,37.78.ESI-MS:m/z 619.5(M+1),636.4(M+18),641.4(M+23),657.4(M+39).C35H34N6O5[618.7].
the corresponding acid chloride was selected from methyl 4-carboxylate benzoyl chloride (74mg) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to prepare (S) -methyl 4- ((4- (((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2- (methyl) oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) carbamoyl) benzoate (6c-7)123mg, white solid, yield 77%, melting point: 129 ℃ and 130 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.54(s,1H,PhNH),8.90(d,J=7.7Hz,1H,NH),8.35(s,1H,triazole-H),8.10(s,4H,Ph-H),7.89(d,J=8.6Hz,2H,Ph-H),7.84(d,J=8.6Hz,2H,Ph-H),7.28–7.14(m,3H,Ph-H),7.07(d,J=6.6Hz,2H,Ph-H),6.94(d,J=8.7Hz,2H,Ph-H),6.90(d,J=6.7Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.48(q,J=8.2Hz,1H,CH),3.91(s,3H,OCH3),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.3,9.1Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),166.15(C=O),165.49(C=O),165.17(C=O),159.03,146.33,139.47,139.00,137.68,135.80,132.51,129.66(2×C),129.34(2×C),129.10(2×C),128.70(2×C),128.58(2×C),127.02,126.83,125.92(2×C),122.94,121.15(2×C),115.10(2×C),55.86,52.91,52.10,51.84,37.90,37.77.ESI-MS:m/z647.5(M+1),664.4(M+18),669.4(M+23).C36H34N6O6[646.7].
the corresponding acid chloride was reacted with (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) using 4-cyanobenzoyl chloride (62mg) to give (S) -4-cyano-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-8)109mg, white solid, yield 71%, melting point: 140 ℃ and 141 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.60(s,1H,PhNH),8.92(d,J=7.8Hz,1H,NH),8.36(s,1H,triazole-H),8.13(d,J=8.3Hz,2H,Ph-H),8.04(d,J=8.3Hz,2H,Ph-H),7.88(d,J=8.9Hz,2H,Ph-H),7.84(d,J=8.9Hz,2H,Ph-H),7.28–7.13(m,3H,Ph-H),7.13–7.00(m,2H,Ph-H),6.94(d,J=8.8Hz,2H,Ph-H),6.90(d,J=6.5Hz,2H,Ph-H),5.17(d,J=16.4Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.47(q,J=8.4Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.6,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.49(C=O),164.62(C=O),159.02,146.28,139.39,138.84,137.69,135.80,132.95(2×C),129.33(2×C),129.10(2×C),129.02(2×C),128.70(2×C),127.02,126.96,125.93(2×C),122.98,121.16(2×C),118.80,115.10(2×C),114.33,55.85,52.10,51.82,37.89,37.77.ESI-MS:m/z 614.3(M+1),631.5(M+18),636.4(M+23).C35H31N7O4[613.7].
the corresponding acid chloride was selected from 2-fluorobenzoyl chloride (44. mu.L) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to give (S) -2-fluoro-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-9)64mg, white solid, yield 42%, melting point: 122 ℃ and 123 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.53(s,1H,PhNH),8.91(d,J=7.8Hz,1H,NH),8.35(s,1H,triazole-H),7.82(s,4H,Ph-H),7.73–7.65(m,1H,Ph-H),7.64–7.55(m,1H,Ph-H),7.38(d,J=10.4Hz,1H,Ph-H),7.33(d,J=7.0Hz,1H,Ph-H),7.26–7.15(m,3H,Ph-H),7.12–7.01(m,2H,Ph-H),6.94(d,J=9.0Hz,2H,Ph-H),6.89(d,J=6.3Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.46(td,J=8.4,5.5Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.92(dd,J=13.4,5.1Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.48(C=O),163.23(C=O),159.33(d,1JCF=247.2Hz),159.02,146.30,138.95,137.69,135.80,133.00(d,3JCF=8.5Hz),130.37(d,4JCF=2.9Hz),129.33(2×C),129.11,128.71(2×C),127.03,126.73,126.01(2×C),125.46(d,2JCF=15.2Hz),125.04(d,4JCF=3.4Hz),122.93,120.45(2×C),116.75,116.53,115.10(2×C),55.86,52.10,51.82,37.89,37.78.ESI-MS:m/z 607.4(M+1),624.5(M+18),629.4(M+23).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 3-fluorobenzoyl chloride (45. mu.L) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to give (S) -3-fluoro-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-10)70mg, white solid, yield 46%, melting point: 120 ℃ and 121 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.43(s,1H,PhNH),8.92(d,J=7.8Hz,1H,NH),8.36(s,1H,triazole-H),7.85(q,J=8.6Hz,5H,Ph-H),7.79(d,J=9.7Hz,1H,Ph-H),7.61(q,J=7.9Hz,1H,Ph-H),7.46(td,J=8.6,2.2Hz,1H,Ph-H),7.21(q,J=7.4,6.8Hz,3H,Ph-H),7.13–7.02(m,2H,Ph-H),6.94(d,J=8.8Hz,2H,Ph-H),6.89(d,J=6.6Hz,2H,Ph-H),5.17(d,J=16.4Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.46(td,J=8.4,5.5Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.0Hz,1H,PhCH),2.70(dd,J=13.5,9.3Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.49(C=O),164.61(d,4JCF=2.4Hz,C=O),162.38(d,1JCF=242.7Hz),159.02,146.32,138.98,137.69(2×C),137.62,135.80,131.07(d,3JCF=7.9Hz),129.34(2×C),129.10,128.71(2×C),127.03,126.77,125.90(2×C),124.38(d,4JCF=2.7Hz),122.94,121.14(2×C),118.98(d,2JCF=21.1Hz),115.10(2×C),114.87,55.85,52.10,51.82,37.88,37.78.ESI-MS:m/z 607.4(M+1),624.5(M+18),629.4(M+23).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 4-fluorobenzoyl chloride (44. mu.L) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to give 52mg of (S) -4-fluoro-N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) benzamide (6c-11), white solid, yield 35%, melting point: 125 ℃ and 126 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.37(s,1H,PhNH),8.91(d,J=7.8Hz,1H,NH),8.35(s,1H,triazole-H),8.06(dd,J=8.6,5.6Hz,2H,Ph-H),7.84(q,J=8.8Hz,4H,Ph-H),7.38(t,J=8.8Hz,2H,Ph-H),7.21(q,J=7.3,6.7Hz,3H,Ph-H),7.07(d,J=6.6Hz,2H,Ph-H),6.94(d,J=8.9Hz,2H,Ph-H),6.89(d,J=6.5Hz,2H,Ph-H),5.17(d,J=16.3Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.46(td,J=8.5,5.6Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.5,5.1Hz,1H,PhCH),2.70(dd,J=13.4,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.18(C=O),165.49(C=O),164.90(C=O),164.55(d,1JCF=247.6Hz),159.02,146.35,139.18,137.69,135.80,131.80(d,4JCF=2.8Hz),130.93(2×C),130.84,129.33(2×C),129.10,128.70(2×C),127.02,126.60,125.88(2×C),122.89,121.08(2×C),115.92(2×C),115.71,115.10,55.86,52.10,51.82,37.89,37.78.ESI-MS:m/z 607.4(M+1),624.4(M+18),629.4(M+23).C34H31FN6O4[606.7].
the corresponding acid chloride was selected from 4-phenylbenzoyl chloride (81mg) and (S) -2(2- (4- (4-aminophenyl) -1H-1,2, 3-triazol-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (5c) to give (S) -N- (4- (1- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -1H-1,2, 3-triazol-4-yl) phenyl) - [1, 68mg of 1' -biphenyl ] -4-carboxamide (6c-12) as a white solid in 41% yield, melting point: 160 ℃ and 161 ℃.
Spectral data:1H NMR(400MHz,DMSO-d6)δ10.41(s,1H,PhNH),8.92(d,J=7.8Hz,1H,NH),8.36(s,1H,triazole-H),8.09(d,J=8.3Hz,2H,Ph-H),7.91(d,J=8.7Hz,2H,Ph-H),7.85(t,J=8.1Hz,4H,Ph-H),7.78(d,J=7.5Hz,2H,Ph-H),7.52(t,J=7.6Hz,2H,Ph-H),7.43(t,J=7.3Hz,1H,Ph-H),7.27–7.16(m,3H,Ph-H),7.07(d,J=6.4Hz,2H,Ph-H),6.94(d,J=9.0Hz,2H,Ph-H),6.90(d,J=6.3Hz,2H,Ph-H),5.17(d,J=16.4Hz,1H,triazoleCH),5.06(d,J=16.3Hz,1H,triazoleCH),4.47(td,J=8.5,5.4Hz,1H,CH),3.76(s,3H,OCH3),3.11(s,3H,NCH3),2.93(dd,J=13.4,5.1Hz,1H,PhCH),2.70(dd,J=13.5,9.2Hz,1H,PhCH).13C NMR(100MHz,DMSO-d6)δ171.19(C=O),165.63(C=O),165.50(C=O),159.02,146.39,143.60,139.56,139.31,137.69,135.80,134.11,129.54(2×C),129.34(2×C),129.11(2×C),128.86(2×C),128.71(2×C),128.63,127.40(2×C),127.07(2×C),127.04,126.53,125.88(2×C),122.89,121.05(2×C),115.10(2×C),55.86,52.10,51.82,37.88,37.78.ESI-MS:m/z 665.4(M+1),682.5(M+18),687.4(M+23),703.5(M+39).C40H36N6O4[664.8].
example 6 in vitro anti-HIV-1 Activity test (TZM-bl cells) of Compounds of interest
The principle is as follows: luciferase reporter Gene experiments (nef Gene deleted HIV-1NL4-3)
The test method comprises the following steps:
anti-HIV-1 infection assay in TZM-bl cells
Infection of TZM-bl cells with a single round of virusThe degree of decrease in the expression level of the luciferase gene was measured to determine the inhibitory activity of the compound against HIV-1 infection. Briefly, 200TCID was used in the presence of varying concentrations of compounds (5a-5c, 6a- (1-12), 6b- (1-12), 6c- (1-12) and PF-74)50The virus of (NL4-3) infects TZM-bl cells. After 2 days of infection, the culture broth was removed and 100 μ L of Bright Glo reagent (Promega, San Luis Obispo, CA) was added to each well and its fluorescence activity was measured using a Victor 2 luminometer. Effective concentration of compound (EC) for inhibiting HIV-1 strain50) Defined as the concentration that results in a 50% decrease in luciferase activity (relative light units) compared to the virus control wells.
Cytotoxicity assays
Cytotoxicity of the synthesized compounds was determined using the CytoTox-Glo fluorescent cytotoxicity kit (purchased from Promega). TZM-bl cells were cultured for 1 day in the presence of different concentrations of compounds (5a-5c, 6a- (1-12), 6b- (1-12), 6c- (1-12) and PF-74), as determined in parallel with the anti-HIV-1 activity assay. The cytotoxicity (CC) of the tested target compound is then determined according to the procedure required by the kit50) I.e., the concentration of the compound of interest required to reduce cell survival by 50%.
TABLE 1 phenylalanine derivatives containing in part 4-phenyl-1, 2, 3-triazole anti-HIV activity, toxicity and selection index (TZM-bl cells)
aEC50: concentration of compound that protects 50% of HIV-1 infected cells from cytopathic effects;
bCC50: (ii) concentration of compound that causes lesions in 50% of cells not infected with HIV-1;
cand (3) SI: coefficient of selectivity, CC50/EC50The ratio of (A) to (B);
PF-74: a class of HIV-1 capsid inhibitors has been reported as positive controls.
And (4) experimental conclusion analysis: as shown in Table 1, the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole synthesized by the invention has obvious anti-HIV-1 activity. For example, compounds 5a, 6a-1, 6a-2, 6a-9, 6a-10, 6a-11, 5b have anti-HIV-1 activity in the range of 3.13-3.99. mu.M, with anti-HIV-1 activity (EC) of compounds 6a-950=3.13±0.91μM,CC50>16.48,SI>5.27) is particularly outstanding and has value for further research.
Claims (6)
1. The phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole, or pharmaceutically acceptable salt, ester or prodrug thereof has a structure shown in a general formula I:
wherein, the amido is ortho-substituted, meta-substituted or para-substituted on the benzene ring; r is: H. acetyl, benzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methoxybenzoyl, 3-methoxybenzoyl, 4-methyl formate benzoyl, 3-methyl formate benzoyl, 2-methyl formate benzoyl, 4-cyanobenzoyl, 3-cyanobenzoyl, 2-fluorobenzoyl, 3-fluorobenzoyl, 4-phenylbenzoyl, 3-phenylbenzoyl, 2-phenylbenzoyl.
2. The phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole according to claim 1, wherein the compound is one of the following compounds:
3. the method for preparing the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole according to claim 1, comprising the following steps: generating an intermediate 2 with Boc-L-phenylalanine (1) as an initial raw material and dichloromethane as a reaction solvent through an amide condensation reaction and N-methyl-4-aminoanisole; then the intermediate 2 is dissolved in a proper amount of dichloromethane, and Boc groups are removed under the action of trifluoroacetic acid to obtain an intermediate 3; then, carrying out amide condensation reaction on the intermediate 3 and azido acetic acid to obtain an intermediate 4 with azido groups; the intermediate 4 and corresponding substituted aminophenylacetylene generate compounds 5a-5c through azide-alkyne Husigen-Click cycloaddition reaction catalyzed by Cu (I) under the condition of sodium ascorbate and copper sulfate pentahydrate; finally, the compounds 5a-5c and corresponding acyl chloride are subjected to acylation reaction to obtain target compounds 6a- (1-12), 6b- (1-12) and 6c- (1-12);
the synthetic route is as follows:
reagents and conditions: (i) n-methyl-4-aminoanisole, 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate, N, N-diisopropylethylamine and dichloromethane are added, and the temperature is changed to room temperature at 0 ℃; (ii) trifluoroacetic acid, dichloromethane, room temperature; (iii) azidoacetic acid, O- (7-azabenzotriazole-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, N, N-diisopropylethylamine and acetonitrile, and the temperature is changed to room temperature at 0 ℃; (iv) corresponding substituted aminophenylacetylene, sodium ascorbate, copper sulfate pentahydrate, water/tetrahydrofuran, room temperature; (v) the corresponding acyl chloride, triethylamine and dichloromethane are cooled to room temperature at 0 ℃;
wherein R is as defined in formula I in claim 1;
the substituted aminophenylacetylene is 2-aminophenylacetylene, 3-aminophenylacetylene or 4-aminophenylacetylene;
the acyl chloride is acetyl chloride, benzoyl chloride, 4-methylbenzoyl chloride, 2-methoxybenzoyl chloride, 3-methoxybenzoyl chloride, 4-methyl formate benzoyl chloride, 4-cyanobenzoyl chloride, 2-fluorobenzoyl chloride, 3-fluorobenzoyl chloride, 4-fluorobenzoyl chloride or 4-phenylbenzoyl chloride.
4. The preparation method of the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole according to claim 3, comprises the following steps:
(1) adding Boc-L-phenylalanine (1) and 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate into dichloromethane, and stirring for 30min under an ice bath condition; adding N, N-diisopropylethylamine and N-methyl-4-aminoanisole into the reaction solution, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium bicarbonate solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, adding a 1N HCl solution for washing, separating the organic phase, adding a saturated sodium chloride solution for washing, drying the organic phase with anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and separating and purifying the obtained crude product by silica gel column chromatography to obtain an intermediate 2;
(2) adding the intermediate 2 obtained in the previous step into dichloromethane, then slowly dropwise adding excessive trifluoroacetic acid into the solution, and stirring for 1h at room temperature; then adding saturated sodium bicarbonate solution to adjust the pH value of the reaction solution to 7, and then adding dichloromethane solution for extraction; separating and taking an organic phase, washing the organic phase for 3 times by using a saturated sodium chloride solution, drying the organic phase by using anhydrous sodium sulfate, filtering, evaporating the solvent by reduced pressure, and separating by using silica gel column chromatography to obtain an intermediate 3;
(3) adding azidoacetic acid and O- (7-azabenzotriazole-1-yl) -N, N, N ', N' -tetramethylurea hexafluorophosphate into acetonitrile, and stirring for 1h under an ice bath condition; then adding the intermediate 3 and N, N-diisopropylethylamine into the solution, removing the ice bath, and stirring at room temperature for 12 h; after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium bicarbonate solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, adding a 1N HCl solution for washing, separating the organic phase, adding a saturated sodium chloride solution for washing, drying the organic phase with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, and separating by silica gel column chromatography to obtain an intermediate 4;
(4) adding the intermediate 4, substituted aminophenylacetylene, sodium ascorbate and copper sulfate pentahydrate into a mixed solvent of tetrahydrofuran and water in a volume ratio of 1:1, and stirring at room temperature for 12 h; after the reaction is finished, adding a proper amount of saturated sodium chloride solution into the reaction solution, extracting with dichloromethane, separating and taking an organic phase, drying with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, and separating by silica gel column chromatography; recrystallizing ethyl acetate/petroleum ether to obtain compounds 5a-5 c;
(5) adding the compounds 5a-5c and triethylamine into dichloromethane, slowly adding corresponding acyl chloride into the dichloromethane under the condition of ice bath and stirring, removing the ice bath, transferring to room temperature, and monitoring by TLC; and after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium chloride solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, drying with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, separating by silica gel column chromatography to obtain a crude product of the target compound, and purifying by using a silica gel preparation plate to obtain pure products 6a- (1-12), 6b- (1-12) and 6c- (1-12) of the target compound.
5. The use of the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole according to claim 1 or 2 in the preparation of drugs for preventing and treating AIDS.
6. An anti-HIV pharmaceutical composition, which is characterized by comprising the phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole or the pharmaceutically acceptable salt thereof according to claim 1 or 2 and one or more pharmaceutically acceptable carriers or excipients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910141019.0A CN109796418B (en) | 2019-02-26 | 2019-02-26 | Phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910141019.0A CN109796418B (en) | 2019-02-26 | 2019-02-26 | Phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109796418A true CN109796418A (en) | 2019-05-24 |
CN109796418B CN109796418B (en) | 2022-03-25 |
Family
ID=66562429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910141019.0A Active CN109796418B (en) | 2019-02-26 | 2019-02-26 | Phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109796418B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108033952A (en) * | 2018-01-30 | 2018-05-15 | 山东大学 | Phenylalanine derivative containing triazole ring and preparation method and application |
-
2019
- 2019-02-26 CN CN201910141019.0A patent/CN109796418B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108033952A (en) * | 2018-01-30 | 2018-05-15 | 山东大学 | Phenylalanine derivative containing triazole ring and preparation method and application |
Non-Patent Citations (2)
Title |
---|
BLAIR WS等: "HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention", 《PLOS PATHOGENS》 * |
SHI, J.A等: "Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor", 《JOURNAL OF VIROLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109796418B (en) | 2022-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107148417B (en) | Benzazepine sulfonamide compounds | |
CN109824756B (en) | Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof | |
CN108033952B (en) | Phenylalanine derivative and the preparation method and application thereof containing triazole ring | |
CN112592331B (en) | Oseltamivir PROTAC compound, preparation method thereof and application thereof in anti-influenza virus drugs | |
JPH07508020A (en) | Retroviral protease inhibitor | |
KR102551018B1 (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof | |
CA2256633C (en) | Selected derivatives of k-252a | |
CN110092779B (en) | Substituted phenyl compound and application thereof | |
EP3101005A1 (en) | Ror gamma (rory) modulators | |
EP1636200A2 (en) | Inhibitors of papilloma virus | |
CN109897088B (en) | Phenylalanine derivative containing N- (2-oxoethyl) benzene sulfonamide and preparation method and application thereof | |
CN109796418B (en) | Phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and preparation method and application thereof | |
KR101941794B1 (en) | Aminosulfonyl compound, preparation method therefor and use thereof | |
CN109836477B (en) | Phenylalanine derivative containing benzothiadiazine-3-ketone 1, 1-dioxide and preparation method and application thereof | |
CN110483417B (en) | DACOs NNRTIs amino acid ester derivative, preparation method, pharmaceutical composition and application thereof | |
KR101630243B1 (en) | Novel compounds, pharmaceutically acceptable salts thereof or optical isomer thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of the viral diseases containing the same as an active ingredient | |
WO2019235553A1 (en) | Azetidine derivative, and prodrug thereof | |
CN106008506B (en) | Substituted purin analog derivative and preparation method and application | |
WO2005111006A1 (en) | Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound. | |
CN112272665B (en) | Process for preparing ritalst | |
CN107739316B (en) | Bromotyrosine alkaloid compound and preparation method and application thereof | |
CN114269338A (en) | Process and intermediates for producing diazaspiro lactam compounds | |
CN115093444B (en) | Naphthalene sulfonamide phosphate small molecular compound and application thereof | |
CN115043902B (en) | Nitrogen substituted macrocyclic nannocystin analogue, its preparation method and use | |
CN110878074B (en) | 2-amido-3, 4-dihydropyran-3-formamide analogue and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |